Details for Patent: 8,217,057

Which drugs does patent 8,217,057 protect, and when does it expire?

Patent 8,217,057 protects XALKORI and is included in two NDAs.

This patent has twenty-five patent family members in twenty-one countries.

Summary for Patent: 8,217,057

Title:	Polymorphs of a c-MET/HGFR inhibitor
Abstract:	This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-py- razol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.
Inventor(s):	Cui; Jingrong Jean (San Diego, CA), Tran-Dube; Michelle Bich (San Diego, CA)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	12/095,116
Patent Claim Types: see list of patent claims	Compound; Composition; Dosage form;

Drugs Protected by US Patent 8,217,057

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No				Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-002	Sep 7, 2023		RX	Yes	No				Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-003	Sep 7, 2023		RX	Yes	Yes				Y

Foreign Priority and PCT Information for Patent: 8,217,057

PCT Information
PCT Filed	November 23, 2006	PCT Application Number:	PCT/IB2006/003383
PCT Publication Date:	June 14, 2007	PCT Publication Number:	WO2007/066185

International Family Members for US Patent 8,217,057

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	057964
Australia	2006323025
Brazil	PI0619420